The 9% Reality: Why Employer Healthcare Costs Keep Outpacing Inflation in 2026
For the third consecutive year, employer-sponsored healthcare costs have exceeded projections. Business Group on Health’s 2026 Employer Health Care Strategy Survey—covering 121 large employers providing coverage for approximately 7.4 million people—reports a median cost trend of 9% for 2026, dropping to 7.6% after plan design changes. This represents the highest single-year forecast in more than a decade (Business Group on Health, 2025).
The compounding effect is the more revealing number. On a compounded basis, employer healthcare costs in 2026 are projected to be 62% higher than they were in 2017 (Business Group on Health, 2025). That is not a cyclical fluctuation. It is a structural shift—one that traditional cost-containment tactics were not designed to address.
The 9% Number, Sourced and Contextualized
Multiple independent surveys converge on the same trajectory. Business Group on Health projects a 9% median cost trend (2025). Mercer’s National Survey of Employer-Sponsored Health Plans forecasts that without cost-reduction measures, increases would reach approximately 9%; with measures, Mercer estimates the increase at 5.8% (Mercer, 2025). SHRM’s employer benefits reporting confirms that employers across firm sizes are projecting cost increases at or above the highest levels seen since the early 2010s (SHRM, 2025).
KFF’s 2025 Employer Health Benefits Survey provides the participant-side picture: annual family coverage reached $26,993, a 6% increase from the prior year (KFF, 2025). Over five years, family coverage costs have risen 26%—outpacing both wage growth (26%) and general inflation (28.6%) on a compounded basis.
The convergence across these sources eliminates the possibility that any single survey is an outlier. The 9% figure is not a forecast from one methodology—it is a consensus across the industry’s most rigorous data collectors.
Cost Driver #1: GLP-1 Spending Pressure
GLP-1 receptor agonists—semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound)—have become the most discussed pharmacy cost variable in employer health plans. Business Group on Health reports that nearly eight in ten employers are already seeing higher demand for GLP-1 medications (Business Group on Health, 2025). Mercer identifies GLP-1s as a top contributor to rising specialty and prescription drug costs (Mercer, 2025).
At approximately $12,000 or more per patient per year, the per-person cost is significant. But the structural pressure is the expanding eligible population: GLP-1s are increasingly prescribed not only for type 2 diabetes but also for obesity, cardiovascular risk reduction, and other chronic conditions. Each indication expansion widens the pool of participants whose treatment costs enter the plan.
The question for plan sponsors is not whether to cover GLP-1 medications—clinical evidence supports their efficacy for approved indications. The question is whether the upstream metabolic risk that leads to GLP-1 prescriptions can be identified earlier, when lower-cost interventions may still change the trajectory. (For an analysis of how GLP-1 coverage and upstream prevention interact, see our examination of the cost of undetected metabolic risk for employers.)
Cost Driver #2: Specialty Drug Acceleration
GLP-1s are the most visible pharmacy cost driver, but they are part of a broader specialty drug acceleration. Mercer’s 2025 data shows that specialty drugs—including biologics, cell and gene therapies, and biosimilars—continue to grow as a share of total pharmacy spend, even as they represent a small fraction of prescriptions filled (Mercer, 2025).
Business Group on Health’s survey confirms that cancer remains the single largest condition driving costs for the fourth consecutive year, with nearly 90% of employers citing it as a top cost contributor (Business Group on Health, 2025). Cancer treatment increasingly involves high-cost specialty drugs, targeted therapies, and immunotherapies—categories where per-treatment costs can reach six figures.
The specialty drug dynamic creates a structural problem for traditional cost management: these medications often produce meaningful clinical outcomes, making crude utilization restrictions counterproductive. The challenge is not reducing access to effective therapies—it is building the analytical infrastructure to identify which populations are on trajectories toward needing them, and whether earlier intervention can reduce or delay that need.
Cost Driver #3: Mental Health Utilization Surge
Mental health has shifted from a benefits line item to a primary cost driver. Business Group on Health reports that nearly three-quarters of employers observed higher rates of employees seeking mental health and substance use disorder treatment, with an additional 17% anticipating future increases (Business Group on Health, 2025).
SHRM’s 2025 Employee Benefits Survey found that 93% of employers offer an Employee Assistance Program and 88% offer mental health coverage, yet utilization gaps persist across demographics—particularly among lower-wage workers and specific age cohorts (SHRM, 2025). The coverage exists. The access, engagement, and outcome measurement often do not.
The cost implication extends beyond direct mental health spending. Untreated or undertreated mental health conditions correlate with higher emergency department utilization, medication non-adherence, absenteeism, and presenteeism—costs that appear in medical claims and productivity metrics, not in the behavioral health budget line. (For an examination of how predictive data approaches to mental health benefits can surface utilization gaps before they become cost crises, see our analysis of the 2026 employer mental health gap.)
Cost Driver #4: Deferred Care Re-Entering the System
The pandemic-era care deferrals continue to generate downstream costs. Mercer reports that rising utilization across services remains a meaningful cost contributor in 2026, as procedures delayed during 2020–2022 work through the system at higher acuity and higher cost (Mercer, 2025).
The mechanism is straightforward: a screening deferred by two years may now reveal a condition at a later stage, requiring more intensive (and expensive) treatment. A chronic condition that went unmanaged during the deferral period may now present with complications that were avoidable with timely care. The claims arriving in 2025 and 2026 are, in many cases, the compound interest on care that was not delivered in 2020 and 2021.
This cost driver is inherently time-limited—the deferred-care backlog is expected to clear over time. But it overlaps with the GLP-1 surge, specialty drug acceleration, and mental health utilization increase, creating a compressed cost environment where multiple cost drivers compound simultaneously rather than arriving sequentially.
Why Traditional Cost-Containment Strategies Are Not Keeping Pace
The dominant employer response to rising costs has historically been plan design changes: raising cost-sharing thresholds, narrowing networks, shifting a larger share to employees. Mercer reports that 59% of employers plan cost-cutting changes in 2026, up from 44% in 2024 (Mercer, 2025).
Business Group on Health CEO Ellen Kelsay has characterized this approach as a “band-aid” that does not address the underlying cost dynamics (Business Group on Health, 2025). The data supports that characterization: employers absorb over 90% of healthcare costs even after plan design changes, and the 9% trend drops only to 7.6% with those changes—a 1.4 percentage-point reduction against a decade-high cost trajectory.
The structural limitation is that cost-shifting addresses who pays, not how much is spent. Raising a cost-sharing threshold does not reduce the incidence of cancer, slow the progression of metabolic disease, or improve mental health engagement. It transfers a portion of a growing cost base to employees—many of whom respond by deferring care, which creates the next cycle of higher-acuity, higher-cost utilization.
What Forward-Looking HR Leaders Are Doing Differently
The employers reporting the most confidence in their cost trajectory share a common characteristic: they are investing in upstream strategies rather than relying exclusively on downstream cost controls.
Population health analytics. Rather than reacting to claims after they arrive, some organizations are analyzing aggregate health data across their workforce to identify which populations are trending toward high-cost conditions—and intervening during the early stages when the cost of intervention is lowest. The CDC’s Diabetes Prevention Program research demonstrated that structured lifestyle intervention in people with pre-diabetes reduced diabetes incidence by 58% at a cost of approximately $500–$800 per participant (CDC). Compare that to $12,000 or more per year for GLP-1 therapy once diabetes is diagnosed. (For a deeper look at how population health data for benefits design can inform this kind of upstream strategy, see our analysis of predictive quality intelligence for employer health outcomes.)
Prevention-first GLP-1 strategy. Rather than treating GLP-1 coverage as a binary yes/no decision, forward-looking employers are pairing GLP-1 access with metabolic risk identification—using predictive health analytics to surface participants whose biometric trends suggest they may be on a trajectory toward conditions GLP-1s treat. The goal is not to restrict access but to expand the intervention window: reaching people at the $800 stage before they arrive at the $12,000 stage.
Mental health integration. Employers moving beyond standalone EAP utilization are embedding mental health screening into primary care workflows, reducing referral barriers, and tracking mental health service utilization by demographic cohort to identify where access gaps drive downstream medical costs. SHRM data shows 93% of employers offer EAPs (SHRM, 2025)—but offering a program and achieving equitable utilization across the workforce are fundamentally different outcomes.
Multi-year measurement horizons. Prevention programs do not generate ROI in a single plan year. Employers evaluating upstream strategies over 3–5 year time horizons—rather than annual budget cycles—capture cost avoidance that quarterly reporting misses. Annual budgets create a structural bias toward cost-shifting because cost-shifting produces immediate, measurable savings. Prevention produces larger savings, but over a longer timeline.
Frequently Asked Questions
Why are employer healthcare costs rising 9% in 2026?
Multiple cost drivers are converging simultaneously: surging demand for GLP-1 medications, accelerating specialty drug costs (with cancer as the top condition for four consecutive years), rising mental health utilization, and deferred care from the pandemic era re-entering the system at higher acuity. Business Group on Health, Mercer, and SHRM all project cost trends at or near 9%—the highest single-year forecast in more than a decade (Business Group on Health, 2025; Mercer, 2025).
What are employers doing to manage rising healthcare costs?
Mercer reports that 59% of employers plan cost-cutting changes in 2026, up from 44% in 2024—primarily through higher cost-sharing and plan design adjustments (Mercer, 2025). However, these measures reduce the 9% trend to only 7.6%. Forward-looking employers are also investing in upstream strategies: population health analytics to identify at-risk populations earlier, prevention-first GLP-1 strategies, integrated mental health approaches, and multi-year measurement frameworks that capture cost avoidance over 3–5 year horizons.
How much do GLP-1 medications cost employers per patient?
GLP-1 receptor agonists cost approximately $12,000 or more per patient per year. Business Group on Health reports that nearly eight in ten employers are seeing higher demand for these medications (Business Group on Health, 2025). The eligible population is expanding as indications broaden beyond type 2 diabetes to include obesity and cardiovascular risk reduction—making GLP-1s one of the fastest-growing pharmacy cost categories in employer health plans.
Published by LifeX Research Corp. LifeX is an employer-sponsored health research organization operating under an ERISA-governed, self-funded framework using licensed third-party administrators. LifeX is not an insurance company. This content is for informational and educational purposes only and does not constitute legal, medical, or financial advice.
